New Marketplace

A Metrics Moonshot

Article · April 13, 2016

By the time I finished reading “Standardizing Patient Outcomes Measurement,” the New England Journal of Medicine article by Michael Porter, Tom Lee, and Stefan Larsson, I was cheering. The authors point out how a “let a thousand flowers bloom” approach to metrics development has resulted in a glut of process measures in health care and slowed progress toward metrics that reflect real outcomes. They decry the artisanal process by which organizations reinvent the metrics wheel over and over but with enough small differences to render broader comparisons of performance useless.

Our team at Weill Cornell Medicine recently compiled an inventory of the metrics by which we are measured by our four largest commercial payers and for our Medicare ACO. We counted 60 individual measures, with a grand total of 2 that apply across the entire group. All track processes rather than outcomes. There are similarities among the other 58 measures but also nuances that introduce a friction into our operations, to which we must devote significant resources to overcoming.

For example, 18% of the measures relate to management of patients who are diabetic. Every payer agrees on measuring the rate at which our attributed patients have an annual retinal eye exam. But while one payer simply measures whether an annual HbA1C level has been documented, another wants the level to be less than 9%. For one payer it is enough that we document prescribing a 180-day supply of a medication, where for another we need to demonstrate that the patient is taking that medication.

Is there is a business case for this complexity? Possibly, if you take the cynical viewpoint that the entities who administer payment for health care services want to set up providers to fail. I don’t believe that’s true — but the quantity of process measures is a real impediment in the quest for value in health care. Payers with a stated goal of improving quality are actively inhibiting progress toward more meaningful outcome measures.

If this patchwork quilt of process measures is the result of a focus on perfection — by specialty societies that choose measures they can control — then let me beg for imperfect uniformity instead. Variability has been linked to poorer outcomes in health care; surely we should apply the same lens to the metrics we use to measure those outcomes.

We’ve heard much recently about moonshots in medicine. This is a call for a metrics moonshot. The International Consortium for Health Outcomes Measurement, which seeks to identify and propagate well validated measures, is a great launching pad. But the planet on which health care needs to land is one where providers, payers and, most importantly, patients, define shared goals for health and measure efforts on how close we all are to achieving those goals. If all parties can devote the time and space to agree on the measures that matter, then health care’s complexity and cost will be reduced. Process measures are the pre-launch equipment checks that ensure our ship will function. Outcomes measures are what will make that giant step forward.

Meaningful outcomes measures will be out of reach as long as we expend our collective energies on reporting processes. Reducing the complexity of that reporting might just be the catalyst that practicing physicians need in order to focus on patient health.

New call for submissions ­to NEJM Catalyst

Now inviting longform articles

Connect

A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.

Learn More »

More From New Marketplace
Dale04_pullquote_disrupting the value-based vs fee-for-service payment model

Disrupting the Payment Model

We should modernize our payment mechanisms to reflect the reality of our digitally enabled lives.

Percentage of Patients Choosing a Reference-Based Pricing Facility for Knee or Hip Replacement Surgery - 2008-2012 - value-based benefit designs

The Evidence for High-Value Benefit Designs

Innovative models are showing promise, but limited transparency and peer-reviewed research hamper expansion.

New Evidence on Stemming Low-Value and Overprescribing - Nudgind Physicians Toward Better Prescribing Practices

New Evidence on Stemming Low-Value Prescribing

New research suggests that deploying strong and surprising messages could help to address overprescribing of opioids and other drugs.

Wang01_pullquote medical devices - medical device innovation in China

Accelerating Medical Device Innovation in China

Promoting collaboration between clinicians, researchers, device-makers, and regulators.

Health Care Costs - Cost Transparency Is the Main Change Needed to Support Patients in Lowering the Cost of Care

Survey Snapshot: Is Transparency the Answer to Rising Health Care Costs?

NEJM Catalyst Insights Council members say that while transparency might be necessary, we have to change the way care is delivered.

Many Stakeholders Share Responsibility for Lowering the Cost of Care

New Marketplace Survey: Patients Lack Information to Reduce the Cost of Care

Efforts to mitigate rising health care costs have left most industry participants — patients, providers, and payers alike — frustrated at the lack of progress. While there is plenty of blame to go around, a significant open question remains: how responsible are patients for reducing costs?

Hip or Knee OA Care Management - Musculoskeletal Institute and Bundled Payment Program at Dell Medical

Bundled Payments Are Moving Upstream

Dell Medical School at The University of Texas at Austin has improved outcomes and reduced costs for musculoskeletal care with a multidisciplinary Musculoskeletal Institute and bundled payment model.

Elements of a Sustainable Complex Care Management Contract

Sustainable Financing for Complex Care Management Is Critical to a Value-Driven Health Care System

Care management should be payer-agnostic at its core.

Comparison of Certain Model Features in Blue Cross NC Blue Premier vs Next-Generation ACO Model vs BCBSMA Alternative Quality Contract

Engineering a Rapid Shift to Value-Based Payment in North Carolina: Goals and Challenges for a Commercial ACO Program

We believe North Carolina can be a model for the nation.

Small Molecule Drugs Facing Generic Competition - Orphan and Non-Orphan Drugs - Orphan Drug Act

It’s Time to Reform the Orphan Drug Act

Three proposals for improving the law to reflect 21st-century drug development practices.

Connect

A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.

Learn More »

Topics

Vertical Integration and Bold Experimentation

Four points on improving value in health care via vertical integration and aggressive experimentation.

Value Based Care

203 Articles

Disrupting the Payment Model

We should modernize our payment mechanisms to reflect the reality of our digitally enabled lives.

Medicare and Medicaid

124 Articles

“You’re Old Without Hearing Aids”— Addressing…

Hearing loss isn’t a normal consequence of aging. But it is associated with a higher…

Insights Council

Have a voice. Join other health care leaders effecting change, shaping tomorrow.

Apply Now